2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10578
    SEN 304 98%
    SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease.
    SEN 304
  • HY-P10595
    Antho-Rwamide II 118904-15-7 98%
    Antho-Rwamide II is a neuropeptide that can be isolated from the sea anemone Anthopleura elegantissima. Antho-Rwamide II can induce contraction of the endothelial muscles of the sea anemone and participate in neurotransmission. Antho-Rwamide II can be used to explore the function of the nervous system in invertebrates.
    Antho-Rwamide II
  • HY-P10599
    Scyliorhinin I 103425-21-4 98%
    Scyliorhinin I is a tachykinin-1 (NK-1) and tachykinin-2 (NK-2) receptor agonist with a Ki value of 0.9 nM for rat submandibular gland NK-1 receptor and 2 nM for hamster bladder NK-2 receptor. Scyliorhinin I has the ability to contract the longitudinal muscles of the guinea pig ileum.
    Scyliorhinin I
  • HY-P1060A
    LPYFD-NH2 TFA 98%
    LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease.
    LPYFD-NH2 TFA
  • HY-P10611
    [D-Ser14]-Humanin 570382-85-3 98%
    [D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease.
    [D-Ser14]-Humanin
  • HY-P10613
    RERMS 148914-08-3 98%
    RERMS are bioactive peptides produced from the active regions of amyloid-β and A4 protein precursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases.
    RERMS
  • HY-P10621
    SHLP-1 98%
    SHLP-1 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-1 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer.
    SHLP-1
  • HY-P10624
    SHLP-5 1191923-95-1 98%
    SHLP-5 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16s ribosomal RNA (MT-RNR2) gene. SHLP-5 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer.
    SHLP-5
  • HY-P10627
    SOD1 (147-153) human 2760733-01-3 98%
    SOD1 (147-153) human is a peptide fragment of Cu/Zn superoxide dismutase (SOD1) with a high propensity to form amyloid fibrils. SOD1 (147-153) human may trigger the aggregation of full-length SOD1 and is a common molecular determinant of familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS).
    SOD1 (147-153) human
  • HY-P10628
    β Amyloid (1-14), human 98%
    β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research.
    β Amyloid (1-14), human
  • HY-P10630
    Pep63 1781242-18-9 98%
    Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research.
    Pep63
  • HY-P10674
    QMT-CBT 98%
    QMT-CBT is a near-infrared aggregation-induced luminescent photon. After activation of caspase1 (Cas1), QMT-CBT undergoes a CBT-Cys click reaction to form a cyclic dimer QMT-Dimer (the first aggregate) and assembles into nanoparticles (the second aggregate), turning the AIE signal "on" to enhance imaging of Alzheimer's disease (AD).
    QMT-CBT
  • HY-P10690
    CCHa1 peptide 98%
    CCHa1 peptide is a signaling peptide that plays a role in inhibiting sleep arousal. It is produced by enteroendocrine cells in the gut and modulates the animal's response to sensory inputs such as mechanical vibrations by acting on specific dopamine neurons in the brain, thereby helping to suppress arousal responses. CCHa1 peptide holds potential for research in fields related to sleep quality and sensory adaptation.
    CCHa1 peptide
  • HY-P10698
    VH-N412 1801681-81-1 98%
    VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
    VH-N412
  • HY-P10737
    CGGK 1253739-14-8 98%
    CGGK is a control peptide of CAQK peptide (HY-P10216).
    CGGK
  • HY-P1075A
    CALP3 TFA 98%
    CALP3 TFA, a Ca2+-like peptide, is a potent Ca2+ channel blocker that activates EF hand motifs of Ca2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca2+]i by modulating the activity of Calmodulin (CaM), Ca2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
    CALP3 TFA
  • HY-P10767
    MD01-67 2468971-42-6 98%
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models.
    MD01-67
  • HY-P10768
    Ro 25-1553 159427-08-4 98%
    Ro 25-1553 is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model.
    Ro 25-1553
  • HY-P10778
    me4 Peptide 98%
    me4 Peptide is a synthetic peptide designed based on the microexon me4 sequence of neuronal CPEB4 protein. me4 Peptide inhibits CPEB4 aggregation. me4 Peptide can be used in the study of disorders associated with autism spectrum disorders.
    me4 Peptide
  • HY-P1078A
    Huwentoxin XVI TFA 98%
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.
    Huwentoxin XVI TFA
Cat. No. Product Name / Synonyms Application Reactivity